Enablement

Enablement requires that a patent's specification teach a person skilled in the art how to make and use the full scope of the claimed invention without undue experimentation. The question is one of law resting on factual findings, and courts weigh factors including the quantity of experimentation needed, the amount of guidance in the specification, the predictability of the field, and the breadth of the claims. The requirement is most demanding where claims are broad and the technology unpredictable, and the Supreme Court's decision in Amgen v. Sanofi reaffirmed that the full claimed scope must be enabled. The opinions collected here address enablement as a validity defence.

31 opinions and orders.

• July 9, 2026 Fed. Cir. Wyeth LLC v. AstraZeneca Pharmaceuticals LP, No. 24-2325 (Fed. Cir. July 9, 2026) Affirmed
• July 7, 2026 E.D. Tex. Smart RF Inc. v. AT&T Mobility LLC, No. 2:24-cv-00195 (E.D. Tex. July 7, 2026) Adopted in Part
• April 16, 2026 Fed. Cir. Teva Pharmaceuticals International GmbH v. Eli Lilly and Company, No. 24-1094 (Fed. Cir. Apr. 16, 2026) Reversed in Part
• March 11, 2026 E.D. Tex. Robert Bosch, LLC v. Westport Fuel Systems Canada, Inc., No. 2:23-cv-00038 (E.D. Tex. Mar. 11, 2026) Adopted in Part
• December 2, 2025 Fed. Cir. Seagen Inc. v. Daiichi Sankyo Company, Ltd., No. 23-2424 (Fed. Cir. Dec. 2, 2025) Reversed
• September 17, 2025 Fed. Cir. Lambeth Magnetic Structures, LLC v. Seagate Technology (US) Holdings Inc., No. 23-1335 (Fed. Cir. Sept. 17, 2025) Reversed in Part
• December 1, 2023 E.D. Tex. Entropic Communications, LLC v. Charter Communications, Inc. et al, No. 2:22-cv-00125 (E.D. Tex. Dec. 1, 2023) Denied
• September 20, 2023 Fed. Cir. Baxalta Incorporated v. Genentech, Inc., No. 22-1461 (Fed. Cir. Sept. 20, 2023) Affirmed
• March 15, 2023 E.D. Tex. U.S. Silica Company v. Amberger Kaolinwerke Eduard Kick GmbH & Co. KG, No. 2:20-cv-00298 (E.D. Tex. Mar. 15, 2023) Denied
• May 6, 2022 E.D. Tex. United Services Automobile Association v. PNC Bank N.A., No. 2:20-cv-00319 (E.D. Tex. May 6, 2022) Adopted
• April 29, 2022 E.D. Tex. United Services Automobile Association v. PNC Bank N.A., No. 2:20-cv-00319 (E.D. Tex. Apr. 29, 2022) Denied
• March 1, 2021 Fed. Cir. Bayer HealthCare LLC v. Baxalta Inc., No. 19-2418 (Fed. Cir. Mar. 1, 2021) Affirmed
• February 11, 2021 Fed. Cir. Amgen Inc. v. Sanofi, No. 20-1074 (Fed. Cir. Feb. 11, 2021) Affirmed
• May 20, 2020 Fed. Cir. McRo, Inc. v. Bandai Namco Games America, No. 19-1557 (Fed. Cir. May 20, 2020) Affirmed in Part
• April 3, 2020 Fed. Cir. Taylor v. Iancu, No. 18-1047 (Fed. Cir. Apr. 3, 2020) Affirmed
• October 30, 2019 Fed. Cir. Idenix Pharmaceuticals LLC v. Gilead Sciences Inc., No. 18-1691 (Fed. Cir. Oct. 30, 2019) Affirmed in Part
• June 20, 2019 Fed. Cir. Enzo Life Sciences, Inc. v. Roche Molecular Systems, Inc., No. 17-2498 (Fed. Cir. June 20, 2019) Affirmed
• July 25, 2018 Fed. Cir. Trustees Of Boston University v. Everlight Electronics Co., No. 16-2576 (Fed. Cir. July 25, 2018) Reversed in Part
• November 13, 2017 Fed. Cir. Promega Corp v. Life Tech, No. 13-1011 (Fed. Cir. Nov. 13, 2017) Affirmed
• October 5, 2017 Fed. Cir. Amgen Inc. v. Sanofi, No. 17-1480 (Fed. Cir. Oct. 5, 2017) Reversed in Part
• August 25, 2017 E.D. Tex. Erfindergemeinschaft UroPep GbR v. Eli Lilly & Co., No. 2:15-cv-1202-WCB (E.D. Tex. Aug. 25, 2017) Denied
• September 29, 2016 E.D. Tex. Perdiem Co LLC v. GPS Logic, LLC, No. 2:15-cv-01216 (E.D. Tex. Sept. 29, 2016) Adopted
• September 12, 2016 E.D. Tex. Core Wireless Licensing S.a.r.l. v. LG Electronics, Inc. et al, No. 2:14-cv-00911 (E.D. Tex. Sept. 12, 2016) Adopted
• August 4, 2015 Fed. Cir. Allergan, Inc. v. Sandoz Inc., No. 14-1275 (Fed. Cir. Aug. 4, 2015) Affirmed
• April 3, 2015 Fed. Cir. Vasudevan Software, Inc. v. MicroStrategy, Inc., No. 14-1094 (Fed. Cir. Apr. 3, 2015) Affirmed in Part
• December 15, 2014 Fed. Cir. Promega Corp v. Life Tech, No. 13-1011 (Fed. Cir. Dec. 15, 2014) Reversed in Part
• March 18, 2014 Fed. Cir. Alcon Research, Ltd. v. Barr Laboratories, Inc., No. 12-1340 (Fed. Cir. Mar. 18, 2014) Affirmed in Part
• February 6, 2014 Fed. Cir. Pfizer Inc. v. Teva Pharmaceuticals USA, No. 12-1576 (Fed. Cir. Feb. 6, 2014) Affirmed
• November 7, 2013 E.D. Tex. Personalized Media Communications, L.L.C. v. Zynga, Inc., No. 2:12-cv-00068 (E.D. Tex. Nov. 7, 2013) Granted
• July 26, 2013 Fed. Cir. Teva Pharmaceuticals USA v. Sandoz Inc., No. 12-1567 (Fed. Cir. July 26, 2013) Affirmed in Part
• June 26, 2013 Fed. Cir. Wyeth v. Abbott Laboratories, No. 12-1223 (Fed. Cir. June 26, 2013) Affirmed